Target intelligence / Profile preview

Organic cation transporter 1 and OATP transporters (OCT1 and OATP)

Target
OCT1 and OATP
Molecular classification
Transporters, OCT1: SLC (solute carrier) family, specifically SLC22A1, OATP: SLC (solute carrier) family, specifically SLCO (formerly SLC21), OCT1: Organic cation transporter, OATPs: Organic anion transporting polypeptide
01

Overview

Organic cation transporter 1 (OCT1) and organic anion transporting polypeptides (OATPs) are membrane-bound solute carrier transporters critical for the uptake of structurally diverse endogenous and exogenous compounds, including many clinically important drugs. OCT1 (SLC22A1) primarily transports organic cations and is important for hepatic uptake and clearance of drugs such as metformin. OATPs (SLCO family) mediate the sodium-independent uptake of large, amphipathic organic anions and some neutral or cationic drugs, playing a vital role in hepatic drug clearance, bile acid and hormone transport, and are important for the pharmacokinetics and safety of numerous drugs, especially statins, antibiotics, and anticancer agents. Both transporter types are highly expressed in the liver and other tissues, are subject to significant genetic variation, and are frequent sites of clinically important drug–drug interactions. Altered function or expression impacts disease risk, drug safety, and therapeutic response, making them important pharmacogenomic biomarkers and therapeutic targets.

Other names
OCT1: SLC22A1, solute carrier family 22 member 1OATP: SLCO family (e.g., SLCO1B1, SLCO1B3, SLCO2B1), organic anion transporter polypeptide, OATPs
02

Mechanism of action

Facilitate cellular uptake of cationic (OCT1) or anionic (OATPs) drugs and metabolites through Na+-independent facilitated diffusion, often acting as exchangers (e.g., exchanging organic cations/anions with other intracellular solutes). Substrate recognition is poly-specific, with overlap between drugs and endogenous molecules.

03

Biological functions

Transport of endogenous and exogenous compoundsUptake of drugs, hormones, toxins, and metabolites across membranesDrug absorption and dispositionBile acid transportHormone transport (steroid, thyroid)Mediating drug–drug interactionsHomeostasis of small molecules (OCT1 for cations, OATPs for anions)
04

Disease associations

Cancer (altered expression affects drug delivery, chemoresistance)Liver disease (fibrosis, cirrhosis, hepatocellular carcinoma, cholestasis)Pharmacogenomics and drug adverse effect risk (variability in transporter function impacts drug toxicity)Cardiovascular disease (via statin PK/PD)Renal diseaseMetabolic disordersDrug–drug interactions affecting therapy efficacy and safety
05

Safety considerations

Drug–drug interactions: Co-administered drugs that are OATP or OCT1 substrates or inhibitors can cause altered pharmacokinetics, leading to toxicity or therapy failureGenetic variation: Polymorphisms in SLCO1B1 (OATP1B1) linked to increased statin-induced myopathy riskAltered expression or function in disease states can impact drug disposition, leading to toxicity, decreased efficacy, or unpredictable responses
06

Interacting drugs

OCT1: Metformin, cimetidine, imatinib, morphine, verapamil

1 more in the full profile.

07

Biomarkers

Expression levels or polymorphisms in OCT1 (SLC22A1) or OATP1B1 (SLCO1B1) genes are used as pharmacogenomic biomarkers to predict drug response, particularly for metformin, statins, and several other drugsLiver and tumor expression of OATPs as possible predictors of chemotherapeutic drug effectiveness or toxicity

Beyond the preview

Go deeper on Organic cation transporter 1 and OATP transporters (OCT1 and OATP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Organic cation transporter 1 and OATP transporters (OCT1 and OATP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call